Home/Pipeline/Prostate Cancer LAI

Prostate Cancer LAI

Prostate Cancer

ApprovedActive

Key Facts

Indication
Prostate Cancer
Phase
Approved
Status
Active
Company

About Tolmar

Tolmar is a private, commercial-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of long-acting injectable drugs. Founded in 2002, it has built a portfolio of approved products sold in over 89 countries, primarily in therapeutic areas like prostate cancer, central precocious puberty, and testosterone replacement therapy. The company operates with a fully integrated model, controlling R&D, manufacturing in Colorado, and sales, which allows for a direct path to market and reliable supply. With over 1,100 employees, Tolmar leverages over 30 years of experience in long-acting injectables to differentiate itself and pursue partnerships for further growth.

View full company profile

Other Prostate Cancer Drugs

DrugCompanyPhase
APVO442Aptevo TherapeuticsPreclinical
APVO452Aptevo TherapeuticsDiscovery
BIO 300Humanetics Corp.Not Specified
OpaganibRedHill BiopharmaPhase 2
MagSense™ PSMA Imaging AgentImagion BiosystemsPre‑clinical
Small-Molecule TherapeuticAIkido LabsPre-clinical
LeronlimabCytoDynPreclinical
CROES RegistryAngioDynamicsPost-Market Registry
Cannabics® PRST-33CNBX PharmaceuticalsDiscovery
HDP-103Heidelberg PharmaPreclinical
ENV105Kairos PharmaPhase 2
AI for Prostate CancerInvenio ImagingResearch